Our Focus — Step 4

 
 

Step 4 — Our current treks

Making genomic test results actionable

Elevation Oncology applies all of its insights towards the development of targeted therapies for novel cancer driver alterations with high unmet patient needs.

Tumor cells often carry many different genomic alterations at once, but only some of these genomic changes drive tumorigenesis and survival. These critical alterations are called oncogenic “driver alterations.”

The identification of driver alterations has changed the way that cancer can be treated. As each new driver is found, new therapies can be developed to specifically target them and precisely inhibit a tumor’s growth and survival.

Driver Alteration
Paired targeted Therapy
Pre-IND
Phase 1
Phase 2
Registrational
Group 3
 

Our Programs

  • NRG 1 Fusions
  • Claudin18.2

NRG 1 Fusions

NRG1 fusions

Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3). HER3 is traditionally activated through binding of its primary ligand, neuregulin-1 (NRG1). The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner protein to create chimeric NRG1 “fusion proteins.” The NRG1 fusion protein is often also able to activate the HER3 pathway, leading to unregulated cell growth and proliferation. Importantly, NRG1 gene fusions are predominantly mutually exclusive with other known genomic driver mutations and are considered a unique oncogenic driver event associated with tumor cell survival.

NRG1 fusions have been identified in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, neuroendocrine, cholangiocarcinomas, and sarcomas. In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion and destabilized the entire ERBB family signaling pathway including the activation of HER2, EGFR, and HER4. In addition to extensive nonclinical characterization and testing, seribantumab has been administered to more than 800 patients across twelve Phase 1 and 2 studies, both as a monotherapy and in combination with various anti-cancer therapies.

We are currently evaluating the safety and efficacy of seribantumab in patients with solid tumors of any origin that have an NRG1 fusion in the Phase 2 CRESTONE study (Clinical Study of Response to Seribantumab in Tumors with Neuregulin-1 (NRG1) Fusions; NCT04383210).

Learn more about Crestone

Claudin18.2

Claudin18.2

Claudin18.2 is a protein expressed across several types of solid tumors including many gastrointestinal cancers such as gastric, gastroesophageal junction (GEJ), and pancreatic cancer. EO-3021 is an ADC containing monomethyl auristatin E (MMAE) payload, a potent anti-mitotic agent. MMAE has been clinically validated as an effective anti-tumor payload and is the cytotoxic component of four U.S. Food and Drug Administration-approved ADCs.

Claudins are a family of proteins acting to maintain the tight junction that controls the interchange of molecules between cells. Claudin18.2 is a specific subtype that is expressed only in cancer cells of the gastric epithelia. When the gastric epithelial cells become malignant, the tight junctions become disrupted, exposing the Claudin18.2 epitopes and allowing them to be targeted by therapeutic antibodies and ADCs.

Currently being evaluated in a Phase 1, dose-escalation study in China, EO-3021 has been granted orphan drug designation and cleared to begin clinical trials in the U.S. by the FDA. The company anticipates initiating a Phase 1 clinical trial in 2023.